Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

Meet the person behind the title – your new FaceOfFacebook
2015-04-29

Kovsies #FaceOfFacebook was born three years ago out of a need to engage with students, and become a virtual friend. Auditions are held every year to choose the new ‘face’ representing the UFS on Facebook. The successful candidate holds the title as #FaceOfFacebook for the next 12 months, attending events, and filming short video clips to post on our Facebook page.

 

The votes have been counted, and we have a winner. After much excitement and a close contest, Nompumelelo Maseko (whose name, fittingly, means ‘success’) emerged victorious from the top six contestants selected by our panel of judges. We sat down with the soft-spoken Mpumi – as her friends call her – to get a sense of the person who will be our ambassador for the next year.

 

What is your field of study, and how far along are you?

I am studying for a BSc degree in Genetics, and I’m currently in my second year. I have a particular interest in the forensic sciences, which fascinate me!

 

Are you originally from Bloemfontein?

No, I am originally from Pretoria.

 

How is it that you ended up here, studying at the UFS?

Before leaving school, I applied to various universities, but my desires and ambitions brought me here.

 

How do you find your residence?

Akasia ladies are big on sisterhood, very supportive. Res life is very enjoyable.

 

What do you hope to accomplish during your term as the #FaceOfFacebook?

I would like to help people become aware of what is taking place on campus. There are many opportunities to be more engaged with what is happening at the varsity. For instance, there are still many people who don’t really know what the #FaceOfFacebook is, and I would like to help inform them about it.

 

What is your motivation in your studies, in taking part in this contest, and in life?

I am intrigued by the function of life forms, the differences that exist at a cellular level.
For this competition, I fed off my love of people, even though I am shy. I also enjoy presenting.


I have my parents to thank as my motivation, as well as meeting and engaging with people. I find that I achieve a broader perspective when I don’t restrict myself to my own opinions, but strive to be open to differing views.

 

Nompumelelo will be appearing in one of her first Facebook videos shortly, so be sure to keep an eye on our Facebook page.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept